Researchers at Rock Health compared digital health funding, deal size, and other metrics in the first half of 2023 with previous years.
The first half of 2023 saw relatively fewer deals, smaller check sizes, and a smaller group of sector investors in digital health, according to a new report from Rockhealth.com.
Funding data also suggested that if trends continue into the second half of 2023, digital health start-ups are on track to have the lowest funding year since 2019, researchers wrote.
The first 6 months of the year saw startups raise $6.1 billion with 244 deals. This equals an average $24.8 million per deal. While 131 deals valued at $3.5 billion took place in quarter 1 of 2023, only 113 deals valued at $2.5 billion were completed in quarter 2, data from the Rock Health Digital Health Venture Funding Database showed.
Total investors in the space also fell in the first half of 2023 to 555. That total was recorded at 775 in the first half of 2022 and 832 during the same time frame in 2021. Most dealmakers in 2023 were also repeat investors, researchers said.
“To us, this signals that generalist and crossover investors are moving away from one-off participation, leaving a smaller group of focused digital health investors to lead sector activity,” they wrote.
Taken together, the data signal a new funding cycle in digital health that may pose challenges to start-ups.
In addition, over 40% of the digital health funding deals so far in 2023 were not publicly labeled, marking the highest proportion of raises without a label since the company began tracking the data in 2011.
“To try and delay valuation haircuts, many digital health players have raised capital without publicly attaching labels to weaker rounds,” researches said. They caution this practice, although it can help start-ups protect their previous valuations, is not a long-term strategy.
Despite the smaller number of active investors in 2023, some that continue to make bets do so with confidence, the authors said.
Just 12 deals in the first half of the year accounted for 37% of total funding dollars, with an average check size of $185 million. This is a similar total to the average mega deal size seen in 2021, at $188 million.
In 2023, “2 mega deals [were] at Series A, 1 at Series B, 2 at Series C, and 6 at Series D or higher,” the authors wrote. Many focused on themes like value-based care enablement and at-home care. Others centered on nonclinical workflow and practice management.
Paradigm, Author Health, MedShift ,and Strive Health were among the start-ups to receive mega deals in the first 6 months of 2023.
When it comes to acquisitions and sell-offs, there were an average of just over 12 acquisitions per month in the first half of the year. The researchers hypothesize one reason this number is so low is that startups may be holding out on accepting bids “they see as lower than they might have received just a few quarters ago or even lower than the sum of their previous raises.” Acquisitions may also be taking place, but are not being publicly announced.
Overall, the reset in funding seen in 2023 “stands to bring fresh and focused perspectives to digital health product development, partnerships, and commercial approaches, as well as team-building,” the researchers wrote. “Though challenging, tough times can serve as a much-needed market correction, right-sizing innovator and investor expectations for a more steady and sustainable future,” they concluded.
Reference
Somaiya M, Knowles M, Krasniansky A, Zweig M, Evans B. H1 2023 digital health funding: a brave new (lower funding) world. Rockhealth.com. July 10, 2023. Accessed July 17, 2023. https://rockhealth.com/insights/h1-2023-digital-health-funding-a-brave-new-lower-funding-world/
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More